Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events

Kilickap S., AK S., Dursun O. U., ŞENDUR M. A. N., Karadurmus N., Demirci U.

Future Oncology, cilt.19, sa.29, ss.2003-2012, 2023 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 19 Sayı: 29
  • Basım Tarihi: 2023
  • Doi Numarası: 10.2217/fon-2023-0014
  • Dergi Adı: Future Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.2003-2012
  • Anahtar Kelimeler: adverse drug reactions, central nervous system, hyperlipidemia, lorlatinib, lung cancer
  • Hacettepe Üniversitesi Adresli: Evet

Özet

The use of tyrosine kinase inhibitors has made a breakthrough in the treatment of non-small-cell lung cancer (NSCLC). Recently, lorlatinib, a third-generation tyrosine kinase inhibitor, has demonstrated significant systemic and intracranial activity in both first-line and subsequent-line therapy in ALK-positive NSCLC patients. In this review, general characteristics of lorlatinib, its efficacy in the treatment of ALK-positive NSCLC patients and the safety of lorlatinib, particularly addressing central nervous system adverse events, are discussed. Management of central nervous system adverse events, which seem to be specific to lorlatinib therapy, is outlined.